Background Iron deficiency (ID) is common in patients with atrial fibrillation/flutter (AF), but its prognostic implications and optimal diagnostic criteria, particularly in those with and without ...
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
Heart disease remains the leading cause of death in the United States, according to a new report. The American Heart Association (AHA) report, published Monday in the journal Circulation, found that ...
Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...
With the transactions stated above, Novo Nordisk owns a total of 25,365,731 B shares of DKK 0.10 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares ...
View all available purchase options and get full access to this article. Division of Medicine, National Amyloidosis Centre, University College London, Royal Free Hospital, United Kingdom (A.P., M.F.).
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once ...
IMMvention partners with Novo Nordisk to co-develop oral therapies for sickle cell disease using BACH1 inhibitors. Novo Nordisk to handle further development, regulatory, and commercialization ...
“We are excited to partner with Novo Nordisk. This collaboration represents a significant milestone for IMMvention and reinforces our vision to address unmet needs in sickle cell disease and ...
A new study found that patients taking GLP-1s to treat type 2 diabetes have a lower risk of developing Alzheimer’s disease, potentially opening the door … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback